UAB Comprehensive Cancer Center

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Melanoma2 trials
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Multiple myeloma1 trial
• Myelodysplastic syndromes1 trial
• Myeloproliferative neoplasms1 trial

Phase

• Phase 22 trials
• Phase 32 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Bristol-Myers Squibb1 trial
• ECOG-ACRIN Cancer Research Group1 trial
• Geron Corporation1 trial
• Hoffmann-La Roche1 trial
• Incyte Corporation1 trial
• and 2 more

Running trials

• Recruiting

  A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05372354· Phase 1/2· Bristol-Myers Squibb· Source

  Contact: Luciano Costa, Site 0002

• Active, not recruiting

  Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

  NCT04509700· Phase 2· Incyte Corporation· Source

• Active, not recruiting

  Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

  NCT02598661· Phase 2/3· Geron Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma1 recruiting

Closed trials

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Hoffmann-La Roche· Source

• Completed

  Endocrine Response in Women With Invasive Lobular Breast Cancer

  NCT02206984· Phase 2· Priscilla McAuliffe· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source